Council News Vol. 7, no. 2

Vaccine Meetingcontinued from page 11
Called FluMist, the vaccine not
only produces antibody but also
mucosal immunity in the nose.
It was developed through a
collaboration joining NIAID
intramural labs, researchers at
the University of Michigan
School of Public Health, and
biotech company Aviron, including clinical testing at six sites
of NIAID's Vaccine and Treatment Evaluation Units and four
clinical sites funded by Aviron.
In a recent efficacy trial, the
vaccine prevented 93 percent of
flu infections in children under
five years of age; 288 children
received one dose of vaccine
(using the same strains as the
traditional influenza vaccine) or
placebo; 1,314 children received
two doses 60 days apart.
Both regimens were safe, and
the vaccine prevented infection
from both flu strains prevalent
at the time, influenza A (H3N2)
and B. The spray was well tolerated and accepted.

NIH newscontinued from page 9
NEW NIH GUIDELINES FOR CONFERENCE
GRANTS
In May, NIH announced updated guidelines for
conference grants, including some specific to
NIAID.
The Institute supports conference grants on a wide range of topics
relevant to its research mission.
Applications must meet certain Conference Grant
criteria to be considered (see box at Guides
right).
For more information, contact: Cost at least $2,500

DAIT-Dr. Lawrence Prograis
301/496-1886
[email protected]
DMID-Dr. Robert Quackenbush
301/496-5644
[email protected]
DAIDS-Ms. Joan Kondratick
301/402-0755
[email protected]
DEA Gregoty Milman
301/496-7291
[email protected]

Apply at least six months
before the meeting
Applications reviewed at
regular (R01) receipt
dates
Applications also
accepted throughout the
year with prior Institute
approval
Usually awarded as a
cooperative agreement

These results were
published in the May
14 New England Journal
of Medicine.
The symposium was
sponsored by Merck,
BIO Council of Biotechnology Centers,
and NIAID.
Held in New York, it
was part of BIO 98,
sponsored by the
Biotechnology Industry Organization.

Novel HIV Therapies-continued from page 16
Ribozyme Gene Therapy and Stem Cell
Transplantation for AIDS Lymphomas
John Zaia, City of Hope National Medical Center
This is a supplement to an existing project that has shown the
safety of infusing genetically engineered, autologous CD34+
peripheral blood progenitor cells in HIV-infected persons.
New work centers on a phase I/IIA gene therapy study using
a double ribozyme targeting tat and rev in AIDS patients with
non-Hodgkin's lymphoma. The PI will test whether genetically
altered cells can engraft and express the transgene after total
marrow ablation.